Loading stock data…
$43.27+0.15 (+0.36%)
Veracyte, Inc.
Veracyte, Inc. in the Healthcare sector is trading at $43.27 with a market capitalization of $3.3B. Wall Street consensus targets $58.42 (12 analysts), implying a +35.0% move over the next 12 months. The stock is currently 29% below its 52-week high of $60.91, remaining 1.6% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $150.32M↑ | $139.07M↓ | $140.64M↑ | $131.87M↑ | $130.16M |
| Gross Profit | $108.55M↑ | $101.16M↓ | $101.97M↑ | $91.28M↑ | $89.77M |
| Operating Income | $22.98M↑ | $22.65M↓ | $39.91M↑ | $23.11M↑ | $15.24M |
| Net Income | $25.49M↓ | $28.71M↓ | $41.15M↑ | $19.14M↑ | -$980,000 |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Dec...